BioAge Labs, Inc. (BIOA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-08

Key Insights

BioAge Labs announced Q1 2026 financial results on May 8, 2026, with the actual earnings data contained in the referenced press release (Exhibit 99.1), which is not included in this 8-K filing itself.
The company is classified as an emerging growth company, indicating it is still in early stages of development and may have reduced disclosure obligations, though it has opted not to use the extended transition period for accounting standards.
Dov Goldstein, M.D., signed as Chief Financial Officer, suggesting the company has established formal financial leadership for quarterly reporting and SEC compliance.
The 8-K filing is relatively routine procedural disclosure for earnings announcement with standard safe harbor language, indicating no material corporate events, acquisitions, leadership changes, or other significant developments beyond quarterly results.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-24

BioAge Labs, Inc. reported its financial results for the year ended December 31, 2025, indicating the company's performance during that period.
The company has updated its corporate deck, which is now available on its investor relations website, providing additional information for investors.
BioAge Labs, Inc. is an emerging growth company, meaning it may take advantage of certain regulatory exemptions and disclosures.

Filed: 2026-01-22

BioAge Labs, Inc. is raising approximately $107.6 million in net proceeds from a public offering of its common stock, which it plans to use for research, clinical development, manufacturing, and other general corporate purposes.
The company is focused on developing product candidates, including BGE-102 and its NLRP3 and APJ programs, which could potentially treat cardiovascular risk and other age-related diseases.
The public offering is being conducted under a shelf registration statement, indicating the company's ability to access the capital markets to fund its ongoing operations and growth initiatives.

Filed: 2026-01-20

BioAge Labs announced the expansion of its oral NLRP3 inhibitor BGE-102 into a Phase 1b/2a proof-of-concept clinical trial for diabetic macular edema (DME), a significant inflammation-driven retinal disease.
The preclinical data showed that BGE-102 demonstrated dose-dependent preservation of retinal vascular integrity and up to 90% preservation of microvascular integrity in a DME model.
BioAge plans to initiate the DME trial in mid-2026, following the completion of the ongoing Phase 1 trial and the initiation of a Phase 2a proof-of-concept trial in patients with obesity and cardiovascular risk factors.

Filed: 2026-01-12

BioAge Labs announced positive interim Phase 1 data for BGE-102, a novel NLRP3 inhibitor, showing rapid and profound reductions in inflammatory markers like hsCRP and IL-6 in obese individuals with elevated cardiovascular risk.
The company achieved an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels, indicating BGE-102's potential as a best-in-class treatment for reducing cardiovascular risk.
BioAge expects to complete the Phase 1 trial and initiate a Phase 2a proof-of-concept study in patients with obesity and cardiovascular risk factors in the first half of 2026, which could further validate BGE-102's therapeutic potential.

Other reports for BioAge Labs, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.